Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy

Surrozen Inc. (NASDAQ: SRZN) submitted an Investigational New Drug application to the FDA for its therapy SZN-8141, aimed at treating diabetic macular edema, leading to a 98.45% increase in its stock price to $32.07. The company plans to initiate a Phase 1b/2a clinical trial, DUET, with patient enrollment expected by late 2026 and initial results anticipated in the second half of 2027. As of June 30, Surrozen reported cash and cash equivalents of $102.0 million.